Literature DB >> 25044052

Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review.

Maria Angela Gobbo1, Mario R Louzã2.   

Abstract

Adults with Attention Deficit Hyperactivity Disorder (ADHD), especially teenagers and young adults, show important car driving impairments, including risky driving, accidents, fines and suspension of driver׳s license. We systematically reviewed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients. We searched several databases for randomized controlled trials (RCTs) published through March, 2013. Fifteen RCTs (the majority with crossover design) evaluated methylphenidate (MPH) immediate-release (MPH-IR), MPH osmotic-controlled oral system (MPH-OROS), MPH transdermal system (MTS), extended-release mixed amphetamine salts (MAS-XR); atomoxetine (ATX) and lisdexamfetamine (LDX). Methods varied widely; including simulators and/or cars and different courses and scenarios. Various outcomes of driving performance, including a 'composite' or 'overall' driving score were considered. In general, stimulants improved driving performance in ADHD patients (either in RCTs conducted in simulators and/or cars). MPH-OROS improved driving performance compared with MAS-XR, placebo, or no-drug conditions. Although MPH-OROS and MPH-IR produced similar improvements during the day, MPH-IR lost its efficacy in the evening. MAS-XR also improved driving performance, but worsened driving performance in the evening. MTS (one study) showed a positive effect, but drug compliance varied widely across patients. LDX had positive effect on driving (two studies with the same sample). Studies with ATX report conflicting results. Improvement was more consistent in teenagers and young adults. In general, treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients. To conclude, treatment with stimulants in therapeutic doses improves driving performance in ADHD patients, especially teenagers and young adults.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Atomoxetine; Attention deficit hyperactivity disorder; Driving; Psychostimulants; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25044052     DOI: 10.1016/j.euroneuro.2014.06.006

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes.

Authors:  Zheng Chang; Patrick D Quinn; Kwan Hur; Robert D Gibbons; Arvid Sjölander; Henrik Larsson; Brian M D'Onofrio
Journal:  JAMA Psychiatry       Date:  2017-06-01       Impact factor: 21.596

Review 2.  Do Pharmaceuticals Improve Driving in Individuals with ADHD? A Review of the Literature and Evidence for Clinical Practice.

Authors:  Craig B H Surman; Ronna Fried; Lauren Rhodewalt; Heidi Boland
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

3.  Comment on Late-Onset ADHD Reconsidered With Comprehensive Repeated Assessments Between Ages 10 and 25.

Authors:  Samuel R Chamberlain; Ulrich Müller
Journal:  Am J Psychiatry       Date:  2018-05-01       Impact factor: 18.112

4.  Concussion Incidence and Recovery Among Youth Athletes With ADHD Taking Stimulant-Based Therapy.

Authors:  Muhammad Ali; Nickolas Dreher; Theodore Hannah; Adam Li; Nek Asghar; Zachary Spiera; Naoum Fares Marayati; John Durbin; Alex Gometz; Mark Lovell; Tanvir Choudhri
Journal:  Orthop J Sports Med       Date:  2021-10-08

Review 5.  The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.

Authors:  Barbara J Sahakian; Annette B Bruhl; Jennifer Cook; Clare Killikelly; George Savulich; Thomas Piercy; Sepehr Hafizi; Jesus Perez; Emilio Fernandez-Egea; John Suckling; Peter B Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-19       Impact factor: 6.237

6.  Mining integrated semantic networks for drug repositioning opportunities.

Authors:  Joseph Mullen; Simon J Cockell; Hannah Tipney; Peter M Woollard; Anil Wipat
Journal:  PeerJ       Date:  2016-01-19       Impact factor: 2.984

Review 7.  Driving and attention deficit hyperactivity disorder.

Authors:  Anselm B M Fuermaier; Lara Tucha; Ben Lewis Evans; Janneke Koerts; Dick de Waard; Karel Brookhuis; Steffen Aschenbrenner; Johannes Thome; Klaus W Lange; Oliver Tucha
Journal:  J Neural Transm (Vienna)       Date:  2015-09-29       Impact factor: 3.575

Review 8.  A systematic review of evidence for fitness-to-drive among people with the mental health conditions of schizophrenia, stress/anxiety disorder, depression, personality disorder and obsessive compulsive disorder.

Authors:  Carolyn A Unsworth; Anne M Baker; Man H So; Priscilla Harries; Desmond O'Neill
Journal:  BMC Psychiatry       Date:  2017-08-31       Impact factor: 3.630

9.  Adult ADHD screening scores and hospitalization due to pedestrian injuries: a case-control study.

Authors:  Alireza Sadeghpour; Homayoun Sadeghi-Bazargani; Saber Ghaffari-Fam; Shaker Salarilak; Mostafa Farahbakhsh; Robert Ekman; Amin Daemi
Journal:  BMC Psychiatry       Date:  2020-09-10       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.